Among the freshly emerging rosacea treatments, botulinum toxin has attracted attention for its prospective efficacy in supplying up to 4 months of symptomatic reduction. Xeomin® appears to show a dose ratio with Botox® of 1:1.33 No substantial differences in protection and efficacy are actually found in experiments comparing Botox® and Xe